Physician profile
Lidia Brown
NPI 1417169491
$5,254.60
in general payments reported to CMS, 2019-2025
16 companies · $947 in 2025
The $947 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,108 · 2020: $133 · 2021: $1,050 · 2022: $618 · 2023: $244 · 2024: $154 · 2025: $947.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,345.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $846.73 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $739.27 | 2019 | |
| Lundbeck LLC | $656.84 | 2019-2025 | Vyepti |
| Sk Life Science, INC. | $625.31 | 2021-2023 | Xcopri |
| Alexion Pharmaceuticals, INC. | $514.73 | 2019-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $462.34 | 2019-2020 | |
| Genzyme Corporation | $322.34 | 2019-2021 | |
| Lilly USA, LLC | $238.04 | 2019-2025 | Kisunla |
| Horizon Therapeutics Plc | $216.24 | 2022-2023 | Uplizna |
| Janssen Biotech, INC. | $202.36 | 2025 | |
| Amgen INC. | $124.99 | 2019 | |
| Portola Pharmaceuticals, LLC | $124.99 | 2019 | |
| Genentech USA, INC. | $100.18 | 2019 | |
| Avanir Pharmaceuticals, INC. | $38.32 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lidia Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.